Patients Clinicians About Investor Center FIND A DOCTOR The Leader in Brachytherapy With higher energy and a shorter half-life than competitors, Cesium Blu by Isoray is proven to be a highly customized and effective treatment for the rapid recovery of patients in the fight against prostate cancer. Isoray is an innovative company that designs and develops state-of-the-art, personalized brachytherapy products that provide a more cost-effective cancer treatment. Isoray employs approximately 40 employees, dedicated to the introduction of a unique isotope for the treatment of both common and also difficult to treat cancers. Based in Richland, in the shadow of the Hanford Nuclear Reservation, Isoray leveraged the expertise in the region to develop a proprietary process for manufacturing a sought after new medical isotope, Cesium 131 used in brachytherapy treatment of cancer. Brachytherapy is a technique that places radiation sources (“seeds’) as close as possible to the tumor site to destroy cancer cells. Cesium 131 has unique characteristics that have evolved into an effective treatment for many types of cancer. Specifically, Cesium 131 is able to provide a highly targeted, fast-acting radiation treatment that is able to deliver its energy in a shorter time period than conventional external beam radiation therapy or other isotopes currently used in brachytherapy, which is not only more cost-effective but typically results in less treatment side-effects. The initial application for Cesium 131 is for the treatment of localized prostate cancer. The fast-acting nature of the treatment allows men to quickly recover from short term side-effects from radiation and return to normal urinary, bowel and sexual function faster than with other brachytherapy isotopes. A growing body of literature supports faster recovery when Cesium 131 brachytherapy is utilized. In addition to serving as a novel, more efficient alternative for prostate brachytherapy treatment, Cesium 131 is showing great promise in other applications that previously had limited treatment alternatives, including recurrent gynecological cancers, brain tumors, sarcomas and other aggressive and recurrent tumors. Leading medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients. The fast-acting nature of the Cesium 131 isotope is well-suited to provide additional targeted radiation at the time of surgery, allowing for the treatment of residual disease while limiting the dose to surrounding healthy tissues. In many cases, the radiation “boost” can be delivered before conventional external beam radiation could even be started — while still delivering higher therapeutic doses. In the case of brain cancer treatment, Isoray has submitted a 510(k) application for a novel delivery system developed in conjunction with the Barrow Neurological Institute (Phoenix, AZ) and is also pursuing a unique code to provide reimbursement. Another exciting new application is for the treatment of recurrent gynecological tumors. Physicians at the University of Kentucky are using Cesium 131 to treat women with a less invasive approach, which historically has required extensive, debilitating surgical procedures. Early results are promising. Isoray Medical is the sole producer of Cesium-131 brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is dedicated to pioneering cost-effective solutions for life beyond a patient’s cancer. Investors Review our SEC Filings, Codes of Conduct, & Management Teams. LEARN MORE Careers We are always looking for talented people to join our team. LEARN MORE Join Us at the Following Events ZERO Prostate Cancer Walk/Run 9/19/2021 ZERO Prostate Cancer Walk/Run 9/25/2021 ASTRO’s 63rd Annual Meeting 10/24/2021 - 10/27/2021 29th Annual Perspectives in Urology: Point Counterpoint 11/18/2021 - 11/20/2021 Recent News Isoray Announces First Quarter Fiscal 2022 Financial Results Nov 10, 2021 Prostate Revenue Increased Year-Over-Year for Second Consecutive Quarter Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed... South Florida Hospital News & Healthcare Report with Chief Research & Development Officer Bill Cavanagh and prominent doctors on treating cancers with Cesium-131 Nov 8, 2021 To read the full article below, please use the navigation arrows at the bottom of each page which become visible when you place your cursor at the bottom of each page. [pdf-embedder... Isoray To Announce First Quarter Fiscal 2022 Financial Results on November 10, 2021 Oct 29, 2021 Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON –October 29, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout... American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131 Sep 28, 2021 RICHLAND, WASHINGTON – September 28, 2021 – The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131... Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues Sep 21, 2021 Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options... Proven • Personalized • Precise Patients & Families Cesium Blu Prostate Cancer Treatment Areas Together Community Doctors & Clinicians Cesium Blu The Data Contact Us Our Products Our company About Us Careers Contact Us Connect with us: Copyright © 2021 Isoray Inc. Terms of Use Privacy Policy Disclosure: The physicians featured on this website may have prior or current relationships with Isoray. These relationships may include, for example: membership on Isoray’s Advisory Board; participation as a clinical investigator in research conducted on Isoray products; provision of consultation or training services; or engagement as a prospective partner in the development of new products. Many of these physicians have received or continue to receive compensation from Isoray in one form or another. The principal nature of a specific physician’s relationship is disclosed on this website adjacent to language featuring that physician. Which of these best describes you? I'm a patient or family member living with cancer. I'm a clinician or doctor. I'm an investor. Other Powered byRightMessage ✕